CHICKEN ANAEMIA VIRUS LIVING, ATTENUATED STRAIN 26P4 Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

chicken anaemia virus living, attenuated strain 26p4

intervet australia pty limited - chicken anaemia virus (living, attenuated) strain 26p4 - unknown - chicken anaemia virus (living, attenuated) strain 26p4 vaccine-viral active 0.0 - active constituent

ATOZET10 MG10 MG Izrael - engleski - Ministry of Health

atozet10 mg10 mg

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 10 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

ATOZET10 MG20 MG Izrael - engleski - Ministry of Health

atozet10 mg20 mg

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 20 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

ATOZET10 MG40 MG Izrael - engleski - Ministry of Health

atozet10 mg40 mg

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 40 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

ATOZET10 MG80 MG Izrael - engleski - Ministry of Health

atozet10 mg80 mg

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 80 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

Feraccru Europska Unija - engleski - EMA (European Medicines Agency)

feraccru

shield tx (uk) limited - ferric maltol - anemia, iron-deficiency - antianemic preparations - feraccru is indicated in adults for the treatment of iron deficiency anaemia (ida) in patients with inflammatory bowel disease (ibd).

Mircera Europska Unija - engleski - EMA (European Medicines Agency)

mircera

roche registration gmbh - methoxy polyethylene glycol-epoetin beta - anemia; kidney failure, chronic - antianemic preparations - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5.1).treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.1).

Rienso Europska Unija - engleski - EMA (European Medicines Agency)

rienso

takeda pharma a/s - ferumoxytol - anemia; kidney failure, chronic - other antianemic preparations - rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (ckd).the diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).

Reblozyl Europska Unija - engleski - EMA (European Medicines Agency)

reblozyl

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - other antianemic preparations - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5.1).reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.1).

Evrenzo Europska Unija - engleski - EMA (European Medicines Agency)

evrenzo

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemic preparations - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).